Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 36
1988 111
1989 158
1990 134
1991 115
1992 136
1993 74
1994 113
1995 106
1996 102
1997 107
1998 98
1999 91
2000 109
2001 125
2002 105
2003 131
2004 148
2005 94
2006 127
2007 90
2008 84
2009 105
2010 137
2011 124
2012 104
2013 100
2014 91
2015 113
2016 106
2017 104
2018 86
2019 44
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

3,315 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.
Segaert S and Hermans C. Am J Clin Dermatol 2017 - Review. PMID 28597181
The typical skin lesion of anti-tumor necrosis factor (TNF)-treated patients is orange-red psoriasiform eczema affecting the flexures, genitalia, scalp, or face, with high susceptibility to bacterial superinfection with Staphylococcus aureus. ...
The typical skin lesion of anti-tumor necrosis factor (TNF)-treated patients is orange-red psoriasiform eczema affecting the f …
Tumor necrosis factor alpha has a crucial role in increased reactive oxygen species production in platelets of mice injected with lipopolysaccharide.
Naime ACA, et al. Platelets 2019. PMID 31076004
LPS stimulates cytokines releasing, including tumor necrosis factor alpha (TNF-α), that is important to ROS production. Platelets, considered inflammatory cells, generate ROS when exposed to LPS in vivo, but not when they are incubated in vitro with this compound. ...
LPS stimulates cytokines releasing, including tumor necrosis factor alpha (TNF-α), that is important to ROS production. Platel …
Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Beukelman T, et al. Ann Rheum Dis 2018. PMID 29440001 Free PMC article.
OBJECTIVE: To determine whether tumour necrosis factor inhibitor (TNFi) use is associated with an increased rate of incident malignancy compared with no TNFi use in the treatment of juvenile idiopathic arthritis (JIA), paediatric inflammatory bowel disease (pIBD) and paediatric plaque psoriasis (pPsO). ...
OBJECTIVE: To determine whether tumour necrosis factor inhibitor (TNFi) use is associated with an increased rate of incident malignan …
Tumor necrosis factor.
Wakefield PE, et al. J Am Acad Dermatol 1991 - Review. PMID 1869638
Tumor necrosis factor is important in systemic and cutaneous defense, homeostasis, and many disease states. The numerous and diverse effects of tumor necrosis factor are best understood when considered as concentration-dependent, with normal homeostasis progressing to defense followed by toxic effects. Understanding tumor necrosis factor is important for the dermatologist as more studies appear in our literature and potential clinical uses of tumor necrosis factor (and possible anti-tumor necrosis factor agents) are realized....
Tumor necrosis factor is important in systemic and cutaneous defense, homeostasis, and many disease states. The numerous and d
Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.
Anderson GM, et al. Curr Opin Pharmacol 2004 - Review. PMID 15251122
The critical pathogenic role of tumor necrosis factor (TNF)alpha in inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease is well established. ...
The critical pathogenic role of tumor necrosis factor (TNF)alpha in inflammatory disorders such as rheumatoid arthritis and in …
Systemic use of tumor necrosis factor alpha as an anticancer agent.
Roberts NJ, et al. Oncotarget 2011 - Review. PMID 22036896 Free PMC article.
Tumor necrosis factor-α (TNF-α) has been discussed as a potential anticancer agent for many years, however initial enthusiasm about its clinical use as a systemic agent was curbed due to significant toxicities and lack of efficacy. ...The therapeutic benefit from TNF-α in ILP is thought to be not only due to its direct anti-proliferative effect, but also due to its ability to increase penetration of the chemotherapeutic agents into the tumor tissue. ...
Tumor necrosis factor-α (TNF-α) has been discussed as a potential anticancer agent for many years, however initial enthusiasm
[Tumor necrosis factor].
Herrmann F and Mertelsmann R. Dtsch Med Wochenschr 1989 - Review. PMID 2646094 German.
Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies.
Stübgen JP. J Neurol 2011 - Review. PMID 21253756
The cytokine, tumor necrosis factor alpha (TNFα), has been implicated in many aspects of immune system development, immune response regulation, and T cell-mediated tissue injury. ...
The cytokine, tumor necrosis factor alpha (TNFα), has been implicated in many aspects of immune system development, immune res …
Bench to bedside: tumor necrosis factor-alpha: from inflammation to resuscitation.
Cairns CB, et al. Acad Emerg Med 2000 - Review. PMID 10958139 Free article.
Proinflammatory mediators such as tumor necrosis factor-alpha (TNF) have been implicated in the pathophysiology in a number of acute disease states. Tumor necrosis factor-alpha can contribute to cell death, apoptosis, and organ dysfunction. Tumor necrosis factor-alpha can be generated with sepsis or ischemia-reperfusion by activation of cell mitogen-activated protein kinases and nuclear factor kappa B, leading to TNF production. ...
Proinflammatory mediators such as tumor necrosis factor-alpha (TNF) have been implicated in the pathophysiology in a number of …
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Maini R, et al. Lancet 1999 - Clinical Trial. PMID 10622295
There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate. ...
There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore inves …
3,315 results
Jump to page
Feedback